Lydia H Pecker1, Sarah Kappa2, Adam Greenfest3, Deepika S Darbari4, Robert Sheppard Nickel5. 1. Division of Hematology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD. 2. Division of Hematology, Children's National Health System, Washington, DC. 3. George Washington University School of Medicine and Health Sciences, Washington, DC. 4. Division of Hematology, Children's National Health System, Washington, DC; George Washington University School of Medicine and Health Sciences, Washington, DC. 5. Division of Hematology, Children's National Health System, Washington, DC; George Washington University School of Medicine and Health Sciences, Washington, DC. Electronic address: rnickel@childrensnational.org.
Abstract
OBJECTIVE: To evaluate the impact of an initiative to increase hydroxyurea use among children with sickle cell anemia (SCA) who presented to the emergency department (ED). STUDY DESIGN: This observational cohort study included children with SCA not taking hydroxyurea who presented to the ED with pain or acute chest syndrome and then attended a Quick-Start Hydroxyurea Initiation Project (Q-SHIP) session. A Q-SHIP session includes a hematologist-led discussion on hydroxyurea, a video of patients talking about hydroxyurea, and a direct offer to start hydroxyurea. RESULTS: Over 64 weeks, 112 eligible patients presented to the ED and 59% (n = 66) participated in a Q-SHIP session a median of 6 days (IQR 2, 20 days) after ED or hospital discharge; 55% of participants (n = 36) started hydroxyurea. After a median follow-up of 49 weeks, 83% (n = 30) of these participants continued hydroxyurea. Laboratory markers of hydroxyurea adherence were significantly increased from baseline: median mean corpuscular volume +8.6 fL (IQR 5.0, 17.7, P < .0001) and median hemoglobin F +5.7% (IQR 2.5, 9.8, P = .0001). Comparing Q-SHIP participants to nonparticipants, 12 weeks after ED visit, participants were more likely to have started hydroxyurea than nonparticipants (53% vs 20%, P = .0004) and to be taking hydroxyurea at last follow-up (50% vs 20%, P = .001). Two years after the implementation of Q-SHIP the overall proportion of eligible patients on hydroxyurea presenting to our ED increased from 56% to 80%, P = .0069. CONCLUSIONS: Participation in a clinic to specifically address starting hydroxyurea after a SCA complication increases hydroxyurea use.
OBJECTIVE: To evaluate the impact of an initiative to increase hydroxyurea use among children with sickle cell anemia (SCA) who presented to the emergency department (ED). STUDY DESIGN: This observational cohort study included children with SCA not taking hydroxyurea who presented to the ED with pain or acute chest syndrome and then attended a Quick-Start Hydroxyurea Initiation Project (Q-SHIP) session. A Q-SHIP session includes a hematologist-led discussion on hydroxyurea, a video of patients talking about hydroxyurea, and a direct offer to start hydroxyurea. RESULTS: Over 64 weeks, 112 eligible patients presented to the ED and 59% (n = 66) participated in a Q-SHIP session a median of 6 days (IQR 2, 20 days) after ED or hospital discharge; 55% of participants (n = 36) started hydroxyurea. After a median follow-up of 49 weeks, 83% (n = 30) of these participants continued hydroxyurea. Laboratory markers of hydroxyurea adherence were significantly increased from baseline: median mean corpuscular volume +8.6 fL (IQR 5.0, 17.7, P < .0001) and median hemoglobin F +5.7% (IQR 2.5, 9.8, P = .0001). Comparing Q-SHIPparticipants to nonparticipants, 12 weeks after ED visit, participants were more likely to have started hydroxyurea than nonparticipants (53% vs 20%, P = .0004) and to be taking hydroxyurea at last follow-up (50% vs 20%, P = .001). Two years after the implementation of Q-SHIP the overall proportion of eligible patients on hydroxyurea presenting to our ED increased from 56% to 80%, P = .0069. CONCLUSIONS: Participation in a clinic to specifically address starting hydroxyurea after a SCA complication increases hydroxyurea use.
Authors: Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins Journal: Am J Hematol Date: 2017-09-28 Impact factor: 10.047
Authors: Marc S Zumberg; Suresh Reddy; Robert L Boyette; Robert J Schwartz; Thomas R Konrad; Richard Lottenberg Journal: Am J Hematol Date: 2005-06 Impact factor: 10.047
Authors: Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: Susan E Creary; Deena J Chisolm; Terah L Koch; Victoria A Zigmont; Bo Lu; Sarah H O'Brien Journal: Pediatr Blood Cancer Date: 2016-01-21 Impact factor: 3.167
Authors: Jane S Hankins; Mary Beth McCarville; Angela Rankine-Mullings; Marvin E Reid; Clarisse L C Lobo; Patricia G Moura; Susanna Ali; Deanne P Soares; Karen Aldred; Dennis W Jay; Banu Aygun; John Bennett; Guolian Kang; Jonathan C Goldsmith; Matthew P Smeltzer; James M Boyett; Russell E Ware Journal: Am J Hematol Date: 2015-11-17 Impact factor: 10.047
Authors: Lisa M Shook; Christina B Farrell; Karen A Kalinyak; Stephen C Nelson; Brandon M Hardesty; Angeli G Rampersad; Kay L Saving; Wanda J Whitten-Shurney; Julie A Panepinto; Russell E Ware; Lori E Crosby Journal: Med Educ Online Date: 2016-11-24
Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168
Authors: Marsha J Treadwell; Lisa Du; Neha Bhasin; Anne M Marsh; Theodore Wun; M A Bender; Trisha E Wong; Nicole Crook; Jong H Chung; Shannon Norman; Nicolas Camilo; Judith Cavazos; Diane Nugent Journal: Front Genet Date: 2022-08-26 Impact factor: 4.772